What is Ori Biotech?
Ori Biotech is a pioneering manufacturing platform dedicated to advancing Cell and Gene Therapy (CGT) production. Founded in 2015 and headquartered in London, United Kingdom, the company aims to enhance throughput, elevate quality, and reduce costs within CGT manufacturing. This strategic focus is crucial for making life-changing therapies more accessible to patients. Ori Biotech's platform is designed to address the critical bottlenecks in CGT production, enabling broader patient access to advanced medical treatments.
How much funding has Ori Biotech raised?
Ori Biotech has raised a total of $139.5M across 3 funding rounds:
Angel/Seed
$9.5M
Series A
$30M
Series B
$100M
Angel/Seed (2020): $9.5M with participation from Delin Ventures, Kindred Capital, and Amadeus Capital Partners
Series A (2020): $30M led by Delin Ventures Limited, Amadeus Capital Partners Limited, Kindred Capital, Northpond Ventures LLC, and Octopus Ventures Limited
Series B (2022): $100M supported by Chimera Abu Dhabi, Delin Ventures, Octopus Ventures, Novalis LifeSciences, Puhua Capital, Northpond Ventures, and Amadeus Capital Partners
Key Investors in Ori Biotech
Kindred Capital
Kindred Capital is a venture capital firm that operates in the Venture Capital & Private Equity industry, focusing on early-stage investments and supporting founders with a long-term vision.
Chimera Abu Dhabi
Chimera Abu Dhabi is an investment entity likely focused on strategic growth opportunities, participating in significant funding rounds for innovative companies.
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm that backs companies aiming to change the world across various sectors, including health technology, providing long-term capital and guidance.
What's next for Ori Biotech?
The recent major strategic investment positions Ori Biotech for accelerated growth and market expansion. This significant capital infusion is expected to fuel further development of its manufacturing platform, enhance operational capabilities, and potentially broaden its market reach. The company's trajectory suggests a move towards scaling its operations to meet the increasing demand for efficient and cost-effective CGT manufacturing solutions, solidifying its role as a key enabler in the advanced therapies landscape.
See full Ori Biotech company page
